TG
Therapeutic Areas
Taiwan Liposome Company Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TLC599 | Osteoarthritis knee pain | Phase 3 |
| TLC590 | Metabolic disorders | Phase 2 |
| TLC502 | Immune disorders | Preclinical |
| TLC501 | Metabolic and immune disorders | Preclinical |
| TLC518 | Type‑2 diabetes (once‑monthly GLP‑1) | Phase 2/3 |
| tLNP CAR‑T | Infectious diseases / regenerative medicine | Preclinical |
| Ampholipad | Post‑surgical pain | Commercial (China) |
Leadership Team at Taiwan Liposome Company
DK
Dr. Keelung Hong
Chairman
GY
George Yeh
CEO
GS
George Spencer‑Green
Chief Medical Officer
AS
Amanda Sung
Head of Finance
VC
Vincent Chang
Vice President, CMC & QA
SF
Sheue Fang Shih
Vice President, Product Development
YT
Yunlong Tseng
Vice President, Research & Development